問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Digestive System Department

Kuang Tien General Hospital

Division of General Internal Medicine

更新時間：2024-06-07

楊勝舜Yang, Sheng-Shun
  • Principal Investigator
  • Clinical Trial Experience (year)

  • yansh2525@gmail.com

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊勝舜

List

99Cases

2020-05-01 - 2025-03-31

Phase II

A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    RO7049389、RO7020531、Vemlidy韋立得、Viread 惠立妥、Baraclude 貝樂克

Participate Sites
6Sites

Recruiting6Sites

2023-08-01 - 2028-06-30

Others

A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Tecentriq (RO5541267) (Atezolizumab)Avastin (RO4876646) (Bevacizumab)RO7092284 (Tiragolumab)RO7247669 (PD1-LAG3)

Participate Sites
5Sites

Recruiting5Sites

2023-10-01 - 2026-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-05-01 - 2024-11-18

Phase I/II

Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infection

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Chimpanzee adenovirus HBV vaccine, 2.Modified Vaccinia Ankara HBV vaccine, 3.HBc-HBs/AS01_B4,

Participate Sites
5Sites

Recruiting5Sites

2007-08-01 - 2010-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-01-01 - 2017-12-31

Phase III

A prospective, randomized, double-blind, placebo-controlled, parallel-group, international multicenter phase III trail of PI-88 in the adjuvant treatment of subjects with hepatitis virus related hepatocellular

  • Condition/Disease

    Postoperative adjuvant therapy for hepatitis virus-related liver cancer

  • Test Drug

    PI-88 or matching placebo

Participate Sites
9Sites

Terminated9Sites

2017-12-01 - 2018-12-20

Others

A Retrospective Chart Review Study of Patients Who Previously Participated in the PATRON Phase III Trial

  • Condition/Disease

    Adjuvant treatment of Post- Resection Hepatocellular Carcinoma

  • Test Drug

    Muparfostat (PI-88)

Participate Sites
10Sites

Terminated8Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of Others-

2007-03-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2015-12-01 - 2020-04-30

Phase III

A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Test Drug

    Pexastimogene Devacirepvec (Pexa Vec)

Participate Sites
6Sites

Terminated6Sites

2013-02-07 - 2020-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 4 5 6 7 8 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB